Lupin receives USFDA approval for two drugs

Pharma major Lupin received approval from the USFDA for two important drugs namely - Clomipramine Hydrochloride Capsules and Potassium Chloride for oral solution USP. 

The company received approval to market Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, which is a generic version of SpecGx LLC’s Anafranil in the US. These are used for the treatment of patients with Obsessive-Compulsive Disorder (OCD). According to the IQVIA MAT data, Anafranil capsules posted annual sales of around US$109.6 million in the US, as of September 2018. 

Additionally, Lupin also received approval to market Potassium Chloride for oral solution USP, 20 mEq, which is a generic version of Pharma Research Software Solution LLC’s Potassium Chloride for Oral Solution. The medication is used for the treatment and prophylaxis of patients with hypokalemia (with or without metabolic alkalosis) for whom dietary management with potassium-rich foods or diuretic dose reduction is inadequate. According to the IQVIA MAT data, the annual sales for Potassium Chloride for oral solution USP, 20 mEq stood at US$105 million in the US, as of September 2018. 

On Monday, at 14:52 hours, the shares of Lupin were trading at Rs. 844.20 per share, down 0.78 per cent. The stock hit a high and low of Rs. 854.20 per share and Rs. 834.10 per share, respectively. Meanwhile, the BSE Sensex was at  35,350.54 , up 369.52 points or 1.06 per cent.